News Releases

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients maintained vIGA 0/1 Deepening of response was observed across all lesional and itch endpoints with

Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest

Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 16-week data expected in Q2 2026 - Phase 3 trial initiation in AD anticipated in 2H 2026 -

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T.

SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 2:00 p.m. E.T.

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up  - Results reinforce continued

Webcast to be held Tuesday, January 6th at 8:00 a.m. ET SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest